LivaNova PLC (NASDAQ:LIVN) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 3.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 146,579 shares of the company’s stock after selling 5,292 shares during the quarter. Federated Hermes Inc. owned about 0.27% of LivaNova worth $7,584,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of LIVN. Headlands Technologies LLC acquired a new stake in LivaNova in the third quarter worth about $72,000. Picton Mahoney Asset Management acquired a new stake in LivaNova in the third quarter worth about $91,000. Vanguard Personalized Indexing Management LLC acquired a new stake in LivaNova in the third quarter worth about $217,000. AlphaMark Advisors LLC acquired a new stake in LivaNova in the third quarter worth about $244,000. Finally, Jump Financial LLC acquired a new stake in LivaNova in the third quarter worth about $273,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Price Performance

NASDAQ LIVN opened at $55.94 on Thursday. The stock’s 50-day moving average price is $53.92 and its two-hundred day moving average price is $50.59. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44. The company has a market cap of $3.02 billion, a PE ratio of 174.81 and a beta of 0.89. LivaNova PLC has a 1 year low of $42.75 and a 1 year high of $59.86.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.10. The firm had revenue of $310.10 million for the quarter, compared to the consensus estimate of $287.65 million. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 EPS. On average, analysts predict that LivaNova PLC will post 3.01 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Mizuho reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research report on Wednesday, March 27th. StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday. Barclays boosted their price target on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 price target on shares of LivaNova in a research report on Wednesday, March 20th. Finally, Robert W. Baird boosted their price target on shares of LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a research report on Thursday, February 22nd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, LivaNova has an average rating of “Moderate Buy” and an average target price of $64.40.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.